Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2021 | 1 |
2022 | 1 |
2023 | 1 |
2024 | 0 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Page 1
Ruxolitinib does not completely abrogate the functional capabilities of TLR4/9 ligand-activated NK cells.
Front Immunol. 2023 Jan 5;13:1045316. doi: 10.3389/fimmu.2022.1045316. eCollection 2022.
Front Immunol. 2023.
PMID: 36685552
Free PMC article.
Optimizing the Procedure to Manufacture Clinical-Grade NK Cells for Adoptive Immunotherapy.
Fernández A, Navarro-Zapata A, Escudero A, Matamala N, Ruz-Caracuel B, Mirones I, Pernas A, Cobo M, Casado G, Lanzarot D, Rodríguez-Antolín C, Vela M, Ferreras C, Mestre C, Viejo A, Leivas A, Martínez J, Fernández L, Pérez-Martínez A.
Fernández A, et al. Among authors: pernas a.
Cancers (Basel). 2021 Feb 2;13(3):577. doi: 10.3390/cancers13030577.
Cancers (Basel). 2021.
PMID: 33540698
Free PMC article.
Item in Clipboard
Cite
Cite